Nu Skin Enterprises Stock Earnings Reports

Nu Skin reported Q1 2026 results in line with expectations: revenue of $320.6 million and adjusted EPS of $0.14. Management highlighted two strategic growth drivers — (1) Prysm iO, an intelligent wellness platform that enables a 15-second fingertip nutritional scan and is being positioned as a household wellness device, and (2) expansion in developing and emerging markets (notably Latin America, Southeast Asia, China and a measured pre-market approach to India). Early Prysm traction: nearly 2 million scans from ~30,000 devices plus 20 million historical biophotonics scans, improving data/algorithms and early increases in subscription metrics. Gross margin trends were stable (adjusted gross margin 67.9%; core Nu Skin gross margin 76.9%), while adjusted operating margin compressed to 3.6% as selling expense rose (investments to reward sales leaders and support growth). Management reiterated disciplined cost control, continued investments in AI and localized manufacturing to improve unit economics, and maintained full-year guidance while providing Q2 guidance of $330–360M revenue and $0.15–0.25 EPS. Balance sheet actions included refinancing credit facilities (extended to 2031), $8M returned to shareholders in the quarter (dividends + buybacks), and $137.3M remaining under the repurchase authorization. Risks called out: macro pressures (tariffs, fuel/oil price increases, consumer wallet strain) and the need for behavior change and leader training to scale Prysm adoption.